Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

2011296 citationsJournal Article

Authors

Ronald B. Natale · Heidelberg University

Sumitra Thongprasert · Heidelberg University

F. Anthony Greco · Heidelberg University

Michael Thomas · Heidelberg University

Chun‐Ming Tsai · Heidelberg University

Patrapim Sunpaweravong · Heidelberg University

David Ferry ·

Abstract

In patients with previously treated advanced NSCLC, vandetanib showed antitumor activity but did not demonstrate an efficacy advantage compared with erlotinib. There was a higher incidence of some AEs with vandetanib.

Topics & Keywords

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 29, Issue 8, pp. 1059-1066

DOI: 10.1200/jco.2010.28.5981

Field-Weighted Citation Impact: 36.21